ClinicalTrials.gg

Program

birelentinib

Also written as “DZD8586”, “Birelentinib” and “DZD8586+R-CHOP”.

Its studies are mostly in Lymphoma, Non-Hodgkin · Lymphoma, Large B-Cell, Diffuse · Leukemia, Lymphocytic, Chronic, B-Cell · Purpura, Thrombocytopenic, Idiopathic, led by Dizal Pharmaceuticals.

Furthest: phase 3, since Aug 18, 202512 company-led studies, 7 open or runningNext primary completion: Nov 23, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Dizal Pharmaceuticals127 open or runningphase 3since Aug 18, 2025Dec 15, 2021Nov 23, 2026phase 1 · NCT07888569

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 15, 2021First study: phase 1 study in Lymphoma, Non-HodgkinFirst studyNCT05176873 · 64 enrolled · United States
  2. Mar 30, 2023Phase 1 study in Lymphoma, Non-HodgkinNCT05824585 · 17 enrolled · United States, Australia
  3. Apr 25, 2023Phase 2 study in Lymphoma, Non-HodgkinNCT05844956 · 17 enrolled · China
  4. Aug 1, 20242 phase 2 studiesNCT06539195, NCT06539182
  5. Jun 16, 2025Phase 2 study in Lymphoma, Large B-Cell, DiffuseNCT07059650 · 150 planned · China
  6. Aug 18, 2025Phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellNCT07154264 · 66 planned · China
  7. Aug 18, 2025Phase 3 study in Leukemia, Lymphocytic, Chronic, B-CellNCT07139873 · 250 planned · China
  8. Dec 8, 2025Phase 2 study in Purpura, Thrombocytopenic, IdiopathicNCT07294365 · 60 planned · China
  9. Jan 26, 2026Phase 1 study in Lymphoma, Non-HodgkinNCT07454863 · 6 enrolled · China
  10. Jul 14, 2026Phase 3 study in Lymphoma, Large B-Cell, DiffuseNCT07712588 · 880 planned · China
  11. Sep 30, 2026Phase 1 study in HealthyNCT07888569 · 26 planned · China

Ahead

  1. Nov 23, 2026Primary completion: phase 1 study in HealthyNCT07888569
  2. Jul 2027Primary completion: phase 2 study in Purpura, Thrombocytopenic, IdiopathicNCT07294365
  3. Sep 2027Primary completion: phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellNCT06539182
  4. Jan 2029Primary completion: phase 3 study in Leukemia, Lymphocytic, Chronic, B-CellNCT07139873

TargetBeta

BTK →LYN →read by rule
“An orally bioavailable non-covalent dual inhibitor of tyrosine-protein kinases Lyn (LYN) and BTK (Bruton's tyrosine kinase; Bruton agammaglobulinemia tyrosine kinase), ”NCIt, by rule

Studies

All 12 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07888569Healthy · China1RecruitingNov 23, 202626
NCT07712588Lymphoma, Large B-Cell, Diffuse · China3Not yet recruitingJan 2031880
NCT07454863Lymphoma, Non-Hodgkin · China1CompletedMar 27, 20266
NCT07294365Purpura, Thrombocytopenic, Idiopathic · China2RecruitingJul 202760
NCT07154264Leukemia, Lymphocytic, Chronic, B-Cell · China2RecruitingDec 202966
NCT07139873Leukemia, Lymphocytic, Chronic, B-Cell · China3RecruitingJan 2029250
NCT07059650Lymphoma, Large B-Cell, Diffuse · China2RecruitingOct 2030150
NCT06539195Lymphoma, Large B-Cell, Diffuse · China2CompletedJun 10, 202659
NCT06539182Leukemia, Lymphocytic, Chronic, B-Cell · China2RecruitingSep 2027155
NCT05844956Lymphoma, Non-Hodgkin · China2CompletedFeb 29, 202417
NCT05824585Lymphoma, Non-Hodgkin · United States, Australia1CompletedJun 30, 202517
NCT05176873Lymphoma, Non-Hodgkin · United States1CompletedMay 11, 202264

How it is read

Names in the registry

  • “DZD8586”, 13 entries
  • “Birelentinib”, 1 entry
  • “DZD8586+R-CHOP”, 1 entry
  • “DZD8586+R-GemOx”, 1 entry
  • “DZD8586+BR”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.